Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently
available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly
causes of transplant failure. We reported previously that patients with high-risk molecular
biomarkers who still have detectable minimal residual disease(MRD) pre-HSCT were at very high
risk of relapse, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated
efficacy in the treatment of patients with recurrent or refractory leukemia and
myelodysplastiv syndrome. It was reported that the combination of decitabine, with busufan
and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was
safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the
efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU/CY) as a
preparative regimen for allo-HSCT in patients with very high-risk AL and detectable MRD
pre-HSCT.